Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EXHALE-2: Dexpramipexole in Severe Eosinophilic Asthma
jRCT2031240072Phase 3Completed
- Sponsor
- Areteia Therapeutics
- Start
- Jun 2024
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of dexpramipexole in eosinophilic asthma (EA) (3 arms), sponsored by Areteia Therapeutics. Primary endpoint: Annualized rate of severe asthma exacerbations over 52 weeks. Started Jun 2024; status: completed.
02
Drugs
dexpramipexole
03
Conditions
eosinophilic asthma (EA)
Beyond the preview
Go deeper on jRCT2031240072.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031240072.